

**THE EFFECTS OF THE *Pseudomonas aeruginosa*-DERIVED PIGMENT,
1-HYDROXYPHENAZINE, ON CALCIUM METABOLISM AND
RELEASE OF PRIMARY GRANULE ENZYMES FROM ACTIVATED
HUMAN NEUTROPHILS *IN VITRO***

by

Grace Josephine Ramafi

B.Sc. (Biology) (Georgia State University, USA)

M.Sc. (Medical Immunology) (UP)

Submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy

in

The Department of Immunology

Faculty of Medicine

University of Pretoria

Pretoria

August 1999



DEDICATED TO MY MOTHER, TEBOGO

SUMMARY

The effects of pathologically-relevant concentrations (0.38-12.5 μ M) of the pro-inflammatory, *Pseudomonas aeruginosa*-derived pigment, 1-hydroxyphenazine (1-HP), on Ca^{2+} metabolism and intracellular cyclic AMP in FMLP (1 μ M)-activated human neutrophils, as well as on the release of myeloperoxidase (MPO) and elastase from these cells, have been investigated *in vitro*. Ca^{2+} fluxes were measured using the combination of a fura-2/AM-based spectrofluorimetric method and radiometric procedures which together enabled the distinction between the net efflux and influx of the cation, while colorimetric and radioimmunoassay methods were used to measure granule enzymes and cAMP respectively.

Coincubation of neutrophils with 1-HP did not affect intracellular cAMP or FMLP-activated release of Ca^{2+} from intracellular stores, but did retard the subsequent decline in the concentration of cytosolic free calcium. These effects of 1-HP on the clearance of Ca^{2+} from the cytosol of activated neutrophils were associated with inhibition of efflux of the cation, probably as a result of the antagonistic effect of 1-HP on the plasma membrane Ca^{2+} -ATPase and are the probable cause of increased release of MPO and elastase from the cells.

Because I was unaware of any pharmacologic strategies to potentiate the activity of the plasma membrane Ca^{2+} -ATPase, thereby overcoming the inhibitory effects of 1-HP on the clearance of Ca^{2+} from the cytosol of FMLP-activated neutrophils, I reasoned that pharmacologic enhancement of the cAMP-regulated endo-membrane Ca^{2+} -ATPase, which sequesters/resequesters the cation into intracellular stores, may offer an alternative strategy to restore Ca^{2+} homeostasis in 1-HP-treated neutrophils. Treatment of neutrophils with intracellular cAMP-elevating agents such as dibutyryl cAMP (cell-permeable analogue), rolipram and GR61170X (selective inhibitors of type 4 phosphodiesterase) and CGS21680 and IB-MECA (selective adenosine type 2a and 3 receptor agonists respectively), and to a much lesser extent with theophylline (non-selective phosphodiesterase inhibitor) neutralized the enhancing effects of 1-HP on elastase release by stimulated neutrophils. However, the β_2 -adrenoreceptor agonists, salbutamol and salmeterol, were ineffective, which

correlated well with the inability of these agents to elevate cAMP in neutrophils.

Dibutyryl cAMP and rolipram were also investigated for their effects on 1-HP-mediated inhibition of the clearance of Ca^{2+} from the cytosol of FMLP-activated neutrophils. Both cAMP-elevating agents neutralized the inhibitory effects of the pigment on removal of Ca^{2+} from the cytosol, resulting in restoration of Ca^{2+} homeostasis to the cells. These observations strengthen the proposed mechanistic link between 1-HP-mediated inhibition of the clearance of cytosolic Ca^{2+} and enhancement of degranulation in stimulated neutrophils.

In conclusion, the *Pseudomonas aeruginosa*-derived pigment, 1-HP, possesses potentially harmful pro-inflammatory properties as a result of interference with the handling of Ca^{2+} by stimulated neutrophils. cAMP-elevating agents, particularly selective type 4 phosphodiesterase inhibitors and adenosine receptor agonists operative at the level of type A_{2a} receptors may be potentially useful in patients colonized by *Pseudomonas aeruginosa* since they antagonize the pro-inflammatory activity of 1-HP. These anti-inflammatory effects of the cAMP-elevating agents are achieved indirectly by increasing the efficiency of the endo-membrane Ca^{2+} -ATPase, which compensates for, and bypasses 1-HP-mediated inhibition of the plasma membrane Ca^{2+} extrusion system.

Key words: Neutrophils, *Pseudomonas aeruginosa*, 1-hydroxyphenazine (1-HP), calcium, cyclic AMP, Dibutyryl cAMP, phosphodiesterase inhibitor, adenosine receptor agonists, rolipram, CGS21680.

SAMEVATTING

Die uitwerking van die patologies-verwante konsentrasies (0.38-12.5 μ M) van die pro-inflammatoriese, *Pseudomonas aeruginosa*-afkomstige pigment, 1-hidroksiefenasien (1-HP), op die Ca^{2+} metabolisme en intrasellulêre sikliese AMP in FMLP (1 μ M)-geaktiveerde mensneutrofiële, sowel as op die vrystelling van miëloperoksidase (MPO) en elastase deur hierdie selle, is *in vitro* ondersoek. Ca^{2+} flukse is bepaal deur gebruik te maak van 'n kombinasie van fura-2 AM-gebaseerde spektrofluorimetriese- en radiometriese metodes wat saam die onderskeid tussen die totale effluks en influks van die kation kon tref, terwyl kolorimetriese en radio-immuunbepalingsmetodes gebruik is om granule-ensieme en cAMP, respektiewelik, te bepaal.

Die behandeling van neutrofiële met 1-HP het geen effek op die intrasellulêre cAMP of FMLP-geaktiveerde vrystelling van Ca^{2+} vanuit die intrasellulêre store gehad nie, maar het die daaropvolgende daling in die konsentrasie van sitosoliese vry kalsium, vertraag. Hierdie uitwerking van 1-HP op die verwydering van Ca^{2+} uit die sitosol van geaktiveerde neutrofiële, het met die inhibisie van die effluks van die kation gepaardgegaan en kan moontlik toegeskryf word aan die antagonistiese uitwerking van 1-HP op die plasmamembraan Ca^{2+} -ATPase en is ook moontlik die oorsaak van die verhoogde vrystelling van MPO en elastase deur die selle.

Aangesien ek onbewus was van enige farmakologiese strategieë wat aangewend kon word om die aktiwiteit van die plasmamembraan Ca^{2+} -ATPase te verhoog om sodoende die inhiberende uitwerking van 1-HP op die verwydering van Ca^{2+} uit die sitosol van FMLP-geaktiveerde neutrofiële te oorkom, het ek geredeneer dat die farmakologiese verhoging van die cAMP-gereguleerde endomembraan- Ca^{2+} -ATPase, wat die kation in die intrasellulêre store sekwestreer of hersekwestreer, 'n alternatiewe strategie mag bied om die Ca^{2+} homeostase te herstel in 1-HP-behandelde neutrofiële. Behandeling van neutrofiële met middels wat intrasellulêre cAMP verhoog bv. dibutiriel cAMP (seldeurlaatbare analoog), rolipram en GR61170X (selektiewe inhibeerders van tipe 4 fosfodiesterase), CGS21680 en IB-MECA (selektiewe adenosien tipe 2a en 3 reseptor agoniste respektiewelik), en teofillien (nie-selektiewe fosfodiesterase inhibeerder), het

die verhogende uitwerking van 1-HP op elastase vrystelling deur gestimuleerde neutrofiele, geneutraliseer, hoewel die effek met teofillien aansienlik kleiner was. Die beta2-adrenoseptor agoniste, salbutamol en salmeterol, was egter oneffektief, wat goed met die onvermoë van hierdie agente om cAMP in neutrofiele te verhoog, gekorreleer het.

Die uitwerking van dibutiriel cAMP en rolipram op die 1-HP-bemiddelde inhibisie van die verwydering van Ca^{2+} uit die sitosol van FMLP-geaktiveerde neutrofiele, is ook ondersoek. Beide cAMP-verhogende middels het die effekte van die pigment op die opruiming van Ca^{2+} vanuit die sitosol, geneutraliseer, wat tot die herstel van die Ca^{2+} -homeostase in die selle gelei het. Hierdie waarnemings versterk die voorgestelde meganistiese skakel tussen die 1-HP bemiddelde inhibisie van die opruiming van sitosoliese Ca^{2+} en die verhoging van degranulasie in gestimuleerde neutrofiele.

Ten slotte, die *Pseudomonas aeruginosa*-afkomstige pigment, 1-HP, besit potensieel skadelike pro-inflammatoriese eienskappe as gevolg van die belemmerende uitwerking daarvan op die hantering van Ca^{2+} deur gestimuleerde neutrofiele. cAMP-verhogende agente, veral die selektiewe tipe 4 fosfodiesterase inhibeerders en adenosien reseptor agoniste werksaam op die vlak van tipe A2a reseptore, mag potensieel bruikbaar wees in pasiënte wat deur *Pseudomonas aeruginosa* gekoloniseer is, aangesien dit die pro-inflammatoriese aktiwiteit van 1-HP, teenwerk. Die anti-inflammatoriese uitwerking van die cAMP-verhogende agente word indirek bereik deur die doeltreffendheid van die endomembraan Ca^{2+} -ATPase te verhoog, wat kompenseer vir die plasmamembraan Ca^{2+} verwyderingsstelsel en die belemmerende uitwerking van 1-HP daarop.

ACKNOWLEDGEMENTS

I would like to sincerely thank the following people:

My promoter, Professor R. Anderson as well as Dr A. J. Theron for their help, unwavering guidance and encouragement;

Deidre Traynor and Elize Victor for the collection of blood samples;

The library personnel, in particular, Martie van der Walt for her help in the collection of literature that made the writing of this thesis possible;

Mrs M. Madgwick for her time spent on the typing of this manuscript;

My colleagues, for their great sense of humour and interest in my work;

My parents and siblings for their love and belief in me.



TABLE OF CONTENTS

| | |
|--|--------|
| SUMMARY..... | i- |
| SAMEVATTING..... | -iii- |
| ACKNOWLEDGEMENTS..... | -v- |
| TABLE OF CONTENTS..... | -vi- |
| LIST OF FIGURES..... | -x- |
| LIST OF TABLES..... | -xii- |
| LIST OF ABBREVIATIONS..... | -xiii- |
| | |
| CHAPTER 1: LITERATURE REVIEW..... | 1 |
| 1.1 INTRODUCTION..... | 2 |
| 1.2 CYSTIC FIBROSIS..... | 2 |
| 2 PHAGOCYTES..... | 6 |
| 3 PROTEASES..... | 9 |
| 3.1 <i>Neutrophil elastase (NE)</i> | 9 |
| 3.2 <i>Pseudomonas aeruginosa elastase (PE)</i> | 13 |
| 4 PIGMENTS..... | 14 |
| 4.1 <i>Pyocyanine (Pyo)</i> | 14 |
| 4.2 <i>1-hydroxyphenazine (1-HP)</i> | 14 |
| 4.3 <i>Phenazine pigment production (Pyo and 1-HP)</i> | 14 |
| 4.4 <i>Effects of pyocyanine and 1-HP on neutrophil function</i> | 18 |
| 4.5 <i>Effects of pyocyanine, 1-HP and PE on ciliated respiratory epithelium</i> | 19 |
| 4.6 <i>Effects of pyocyanine and 1-HP on lymphocyte function</i> | 20 |
| 4.7 <i>Effects of pyocyanine on other cell types</i> | 21 |
| 5 CALCIUM AND cAMP AS INTRACELLULAR MESSENGERS..... | 21 |
| 6 cAMP-BASED ANTI-INFLAMMATORY STRATEGIES..... | 25 |
| 7 cAMP-ELEVATING AGENTS..... | 25 |
| 7.1 <i>Dibutyryl cAMP</i> | 25 |



| | | |
|---------|---|----|
| 7.1.1 | <i>Anti-inflammatory activities of dibutyryl cAMP</i> | 25 |
| 7.2 | <i>β₂-adrenoreceptor agonists</i> | 26 |
| 7.2.1 | <i>Salmeterol and salbutamol</i> | 26 |
| 7.2.1.1 | <i>Anti-inflammatory effects of salbutamol</i> | 27 |
| 7.2.1.2 | <i>Anti-inflammatory effects of salmeterol</i> | 27 |
| 7.3 | <i>Phosphodiesterase inhibitors</i> | 29 |
| 7.3.1 | <i>Theophylline</i> | 30 |
| 7.3.1.1 | <i>Anti-inflammatory effects of theophylline</i> | 30 |
| 7.3.2 | <i>Rolipram</i> | 31 |
| 7.3.2.1 | <i>Anti-inflammatory effects of rolipram</i> | 31 |
| 7.3.4 | <i>Adenosine receptor agonists</i> | 32 |
| 7.3.4.1 | <i>Adenosine A1 receptors</i> | 33 |
| 7.3.4.2 | <i>Adenosine A2 receptors</i> | 35 |
| 7.3.4.3 | <i>Adenosine A3 receptors</i> | 37 |
| 7.3.4.4 | <i>Anti-inflammatory effects of A2a receptor agonists</i> | 37 |
| 8 | THE AIM OF THE STUDY..... | 40 |

| | |
|--|----|
| CHAPTER 2: EXPOSURE OF FMLP-ACTIVATED HUMAN NEUTROPHILS TO THE <i>Pseudomonas aeruginosa</i> -DERIVED PIGMENT, 1-HYDROXYPHENAZINE (1-HP), IS ASSOCIATED WITH IMPAIRED CALCIUM EFFLUX AND POTENTIATION OF PRIMARY GRANULE ENZYME RELEASE..... | 41 |
|--|----|

| | | |
|---------|--|----|
| 2.1 | INTRODUCTION..... | 42 |
| 2.2 | METHODS..... | 42 |
| 2.2.1 | <i>Preparation of the pigment, 1-hydroxyphenazine</i> | 42 |
| 2.2.2 | <i>Chemicals and reagents</i> | 43 |
| 2.2.3 | <i>Preparation of neutrophils</i> | 43 |
| 2.2.4 | <i>Elastase and MPO release</i> | 43 |
| 2.2.5 | <i>Spectrofluorimetric measurement of Ca²⁺ fluxes</i> | 44 |
| 2.2.6 | <i>Radiometric assessment of Ca²⁺ fluxes</i> | 45 |
| 2.2.6.1 | <i>⁴⁵Ca²⁺-efflux out of FMLP-activated neutrophils</i> | 45 |
| 2.2.6.2 | <i>⁴⁵Ca²⁺-influx into FMLP-activated neutrophils</i> | 46 |

| | | |
|--------|---|----|
| 2.2.7 | <i>Radiometric assessment of Na⁺ influx</i> | 47 |
| 2.2.8 | <i>Intracellular cAMP levels</i> | 47 |
| 2.2.9 | <i>cAMP-dependent Protein Kinase A (PKA) activity</i> | 48 |
| 2.2.10 | <i>Intracellular ATP levels</i> | 48 |
| 2.2.11 | <i>Statistical analysis</i> | 48 |
| 2.3 | RESULTS | 49 |
| 2.3.1 | <i>The effects of 1-HP on elastase and MPO release</i> | 49 |
| 2.3.2 | <i>The effects of 1-HP on the fura-2 responses of FMLP-activated neutrophils</i> | 52 |
| 2.3.3 | <i>⁴⁵Ca²⁺ fluxes in activated neutrophils</i> | 52 |
| 2.3.4 | <i>Efflux of ⁴⁵Ca²⁺ from FMLP-activated human neutrophils</i> | 56 |
| 2.3.5 | <i>Influx of ⁴⁵Ca²⁺ into FMLP-activated human neutrophils</i> | 56 |
| 2.3.6 | <i>²²Na⁺ fluxes in neutrophils</i> | 60 |
| 2.3.7 | <i>Intracellular cAMP levels</i> | 60 |
| 2.3.8 | <i>Intracellular ATP levels</i> | 60 |
| 2.3.9 | <i>cAMP-dependent protein kinase A (PKA)</i> | 60 |
| 2.4 | DISCUSSION | 62 |

| | | |
|---|--|----|
| CHAPTER 3: THE EFFECTS OF CONVENTIONAL INTRACELLULAR cAMP-ELEVATING AGENTS ON 1-HYDROXYPHENAZINE-MEDIATED INTERFERENCE WITH THE CLEARANCE OF CYTOSOLIC CALCIUM AND ENHANCEMENT OF ELASTASE RELEASE FROM FMLP-ACTIVATED NEUTROPHILS | | 66 |
|---|--|----|

| | | |
|-------|--|----|
| 3.1 | INTRODUCTION | 67 |
| 3.2 | MATERIALS AND METHODS | 68 |
| 3.3 | RESULTS | 69 |
| 3.3.1 | <i>Effects of the various cAMP-elevating agents on elastase release</i> .. | 69 |
| 3.3.2 | <i>Effects of the cAMP-elevating agents on 1-HP-mediated alterations in the fura-2 responses of FMLP-activated neutrophils</i> | 75 |

| | | | |
|---|---|-----|-----|
| 3.3.3 | <i>Effects of theophylline, salbutamol and salmeterol on neutrophil cAMP levels.....</i> | 80 | |
| 3.4 | DISCUSSION..... | 83 | |
| | | | |
| CHAPTER 4: INVESTIGATION OF THE EFFECTS OF ADENOSINE RECEPTOR AGONISTS ON 1-HYDROXYPHENAZINE-MEDIATED ENHANCEMENT OF RELEASE OF ELASTASE FROM ACTIVATED NEUTROPHILS AND ITS RELATIONSHIP TO ALTERATIONS IN INTRACELLULAR cAMP LEVELS..... | | | 85 |
| 4.1 | INTRODUCTION..... | 86 | |
| 4.2 | MATERIALS AND METHODS..... | 87 | |
| 4.3 | RESULTS..... | 88 | |
| 4.3.1 | <i>Effects of the adenosine receptor agonists on elastase release from FMLP/CB-activated neutrophils.....</i> | 88 | |
| 4.3.2 | <i>Effects of the A2a adenosine receptor antagonist (ZM241385) on CGS21680 and IB-MECA-mediated interference with 1-HP-induced enhancement of elastase release.....</i> | 88 | |
| 4.3.3 | <i>Effects of CPA, CGS21680 and IB-MECA on neutrophil cAMP levels.....</i> | 88 | |
| 4.4 | DISCUSSION..... | 96 | |
| | | | |
| CHAPTER 5: CONCLUSIONS..... | | | 99 |
| 5.1 | <i>Conclusions.....</i> | 100 | |
| | | | |
| REFERENCES..... | | | 101 |
| APPENDICES..... | | | 133 |

LIST OF FIGURES

- Figure 1:** Schematic representation of the pathogenesis of respiratory abnormalities in cystic fibrosis
- Figure 2:** Molecular structures of pyocyanine and its degradation product, 1-hydroxyphenazine (1-HP)
- Figure 3:** Structure and numbering system of the phenazine nucleus
- Figure 4:** Diagrammatic representation of release of inositol triphosphate (IP₃) and diacylglycerol (DAG) as second messengers.
- Figure 5:** Molecular structure of cyclopentyladenosine (CPA)
- Figure 6:** Molecular structure of 2-[p-(2-carboxyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)
- Figure 7:** Effects of varying concentrations of 1-HP (0.38-12.5µM) on the release of elastase and MPO from FMLP/CB-activated neutrophils (17 experiments)
- Figure 8:** Effects of varying concentrations of 1-HP (0.38-12.5µM) on the release of elastase and MPO from FMLP/CB-activated neutrophils (1 experiment)
- Figure 9:** FMLP-activated fura-2 fluorescence responses
- Figure 10:** Fluxes of radiolabelled calcium following exposure of neutrophils to FMLP
- Figure 11:** Kinetics of efflux of radiolabelled calcium out of resting and FMLP-activated neutrophils
- Figure 12:** Kinetics of influx of radiolabelled calcium into unstimulated and FMLP-activated neutrophils
- Figure 13:** Molecular structure of 2-chloro-5-isopropyl-7-phenyl-imidazo[1,5-b]pyridazine (GR61170X)
- Figure 14:** Effects of dibutyrylcAMP (0.01-4mM) on the release of elastase from FMLP/CB-activated neutrophils
- Figure 15:** Effects of salmeterol and salbutamol (0.1 and 1µM) on the release of elastase from FMLP/CB-activated neutrophils

- Figure 16:** Effects of theophylline (9-150 μ M) on the release of elastase from FMLP/CB-activated neutrophils
- Figure 17:** Effects of rolipram (10-1000nM) on the release of elastase from FMLP/CB-activated neutrophils
- Figure 18:** Effects of GR61170X (1-100nM) on the release of elastase from FMLP/CB-activated neutrophils
- Figure 19:** FMLP-activated fura-2 fluorescence responses
- Figure 20:** Effects of theophylline (150 μ M) on cAMP levels in unstimulated and FMLP-activated neutrophils
- Figure 21:** Effects of salmeterol (1 μ M) and salbutamol (1 μ M) on cAMP levels in unstimulated and FMLP-activated neutrophils
- Figure 22:** Effects of the adenosine A1 receptor agonist, CPA (0.01-1 μ M) on the release of elastase from FMLP/CB-activated neutrophils in the presence and absence of 1-HP (12.5 μ M)
- Figure 23:** Effects of the adenosine A2a receptor agonist, CGS21680 (0.01-1 μ M) on the release of elastase from FMLP/CB-activated neutrophils in the presence and absence of 1-HP (12.5 μ M)
- Figure 24:** Effects of the adenosine A3 receptor agonist, IB-MECA (0.01-1 μ M) on the release of elastase from FMLP/CB-activated neutrophils in the presence and absence of 1-HP (12.5 μ M)
- Figure 25:** Effects of ZM241385 (2.5 μ M) on the release of elastase from FMLP/CB-activated control neutrophils and from neutrophils coincubated with CGS21680 (1 μ M) in the presence and absence of 1-HP (12.5 μ M)
- Figure 26:** Effects of ZM241385 (2.5 μ M) on the release of elastase from FMLP/CB-activated control neutrophils and coincubated with IB-MECA (1 μ M) in the presence and absence of 1-HP (12.5 μ M)
- Figure 27:** Effects of CGS21680 (1 μ M) on cAMP levels in unstimulated and FMLP-activated neutrophils in the presence and absence of 1-HP (12.5 μ M)
- Figure 28:** Effects of IB-MECA (1 μ M) on cAMP levels in unstimulated and FMLP-activated neutrophils in the presence and absence of 1-HP (12.5 μ M)

LIST OF TABLES

- Table 1:** Peak cytosolic calcium concentrations $[Ca^{2+}]_i$ and time taken for these to decline to half peak values in FMLP-activated control and 1-HP-treated neutrophils
- Table 2:** The effects of varying concentrations (3.1-12.5 μ M) of 1-HP on the efflux of $^{45}Ca^{2+}$ of FMLP-activated neutrophils
- Table 3:** Peak intracellular calcium concentrations $[Ca^{2+}]_i$ and the time taken for these to decline to half peak values in control and 1-HP-treated neutrophils in the presence and absence of rolipram and dibutyryl cAMP
- Table 4:** Peak intracellular calcium concentrations $[Ca^{2+}]_i$ and the time taken for these to decline to half peak values in FMLP-activated neutrophils treated with salbutamol, salmeterol and theophylline

LIST OF ABBREVIATIONS

| | |
|--------------------------------|---|
| ATP | --> Adenosine triphosphate |
| BAL | --> Bronchoalveolar lavage |
| Ca ²⁺ | --> Calcium ion |
| ⁴⁵ Ca ²⁺ | --> Calcium-45 chloride |
| CaBP | --> Calcium binding protein |
| cAMP | --> Adenosine 3', 5'-monophosphate |
| CBF | --> Ciliary beat frequency |
| cDNA | --> Copy deoxyribonucleic acid |
| CF | --> Cystic Fibrosis |
| CFTR | --> Cystic Fibrosis Transmembrane Conductance regulator |
| Cl ⁻ | --> Chloride |
| CPA | --> Cyclopentyladenosine |
| DAG | --> Diacylglycerol |
| DNA | --> Deoxyribonucleic acid |
| ELF | --> Epithelial lining fluid |
| FMLP | --> N-formyl-methyl-leucyl-phenylalanine |
| FMLP/CB | --> N-formyl-methyl-leucyl-phenylalanine/cytochalasin-B |
| FURA-2/AM | --> 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxyl]-2-(2'-amino-5-'-methylphenoxy)-ethane-N,N,N',N'-tetra-acetic pentaacetoxy methylester oil |
| GSH | --> Glutathione |
| H ₂ O | --> Water |
| H ₂ O ₂ | --> Hydrogen peroxide |
| HLMC | --> Human lung mast cell |
| 1-HP | --> 1-Hydroxyphenazine |
| HOCl | --> Hypochlorous acid |
| IgA | --> Immunoglobulin A |
| IgE | --> Immunoglobulin E |
| IgG | --> Immunoglobulin G |
| IL | --> Interleukin |



| | |
|-----------------------------|---|
| IP ₃ | --> Inositol triphosphate |
| LPS | --> Lipopolysaccharide |
| MPO | --> Myeloperoxidase |
| mRNA | --> Messenger ribonucleic acid |
| Na ⁺ | --> Sodium ion |
| NaCl | --> Sodium Chloride |
| NADPH | --> Nicotinamide-adenine-dinucleotide-phosphate-hydrogenase |
| NE | --> Neutrophil elastase |
| NO | --> Nitric Oxide |
| O ₂ ⁻ | --> Superoxide |
| PAF | --> Platelet-activating-factor |
| PDE | --> Phosphodiesterase |
| PE | --> <i>Pseudomonas aeruginosa</i> elastase |
| PIP ₂ | --> Phosphatidylinositol-4,5-biphosphate |
| PKC | --> Protein kinace C |
| PLC | --> Phospholipase C |
| PMA | --> Phorbol-12-myristate acetate |
| Pyo | --> Pyocyanine |
| R | --> Receptor |
| SCID | --> Severe combined immunodeficiency |
| SLPI | --> Secretory leukoprotease inhibitor |
| SOD | --> Superoxide dimutase |
| TNF α | --> Tumor necrosis factor alpha |
| W ⁺ | --> Wild type |